Patents by Inventor David A. Schwartz

David A. Schwartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12291738
    Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: May 6, 2025
    Assignees: The University of Chicago, EMD Millipore Corporation
    Inventors: David A. Schwartz, Jimmy Williams, Xinfang Zhao, Chunfang Zhao, William B. Busa, Stephen J. Kron, Amy Catherine Flor
  • Publication number: 20250020643
    Abstract: The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids.
    Type: Application
    Filed: September 19, 2024
    Publication date: January 16, 2025
    Inventors: David A. SCHWARTZ, Stephen J. KRON
  • Patent number: 12168674
    Abstract: The present disclosure provides reagent compounds, reactive biopolymeric compounds, and methods of making and using these materials for the rapid and efficient synthesis and purification of biopolymeric compounds at low cost. The materials and methods yield highly pure synthetic biopolymeric compounds, including synthetic oligonucleotides and polypeptides, and reduce or eliminate the need for toxic solvents in the synthetic process.
    Type: Grant
    Filed: December 8, 2023
    Date of Patent: December 17, 2024
    Assignee: Oligo Foundry, Inc.
    Inventors: David A. Schwartz, Jimmy H. Williams
  • Patent number: 12123874
    Abstract: The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: October 22, 2024
    Assignees: CELL IDX, INC., THE UNIVERSITY OF CHICAGO
    Inventors: David A. Schwartz, Stephen J. Kron
  • Publication number: 20240271215
    Abstract: Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia.
    Type: Application
    Filed: April 10, 2024
    Publication date: August 15, 2024
    Inventors: David A. Schwartz, Tasha E. Fingerlin, Weiming Zhang
  • Patent number: 11976328
    Abstract: Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: May 7, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: David A. Schwartz, Tasha E. Fingerlin, Weiming Zhang
  • Publication number: 20240085424
    Abstract: The present disclosure provides high-performance immunoreagents for use in a variety of immunologic assays and other related techniques. The immunoreagents comprise a primary antibody and a bridging antigen, wherein the bridging antigen is recognized by a detectable secondary antibody with high affinity. Also provided are compositions comprising panels of immunoreagents specific for multiple different target antigens and compositions comprising pairs of primary immunoreagents and their complementary detectable secondary antibodies. The paired primary immunoreagents and secondary antibodies are useful in a variety of immunologic assays, particularly in highly multiplexed assays, where the structure of the bridging antigen is varied in tandem with variation in the detectable secondary antibody, such that a multiplicity of immunoreagents are provided that are capable of simultaneously detecting a multiplicity of target antigens in a single assay.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 14, 2024
    Inventor: David A. SCHWARTZ
  • Patent number: 11891069
    Abstract: This document describes techniques, apparatuses, and systems for a grid-based road model with multiple layers. An example road-perception system generates a roadway grid representation that includes multiple cells. The road-perception system uses data from multiple information sources to generate a road model that includes multiple layers. Each layer represents a roadway attribute of each cell in the grid and includes one or more layer hypotheses. In this way, the described techniques and systems can provide an accurate and reliable road model and quantify uncertainty therein.
    Type: Grant
    Filed: February 23, 2023
    Date of Patent: February 6, 2024
    Assignee: Aptiv Technologies Limited
    Inventors: Bin Jia, Sana Sarfraz, David A. Schwartz, Kumar Vishwajeet
  • Patent number: 11867696
    Abstract: The present disclosure provides high-performance immunoreagents for use in a variety of immunologic assays and other related techniques. The immunoreagents comprise a primary antibody and a bridging antigen, wherein the bridging antigen is recognized by a detectable secondary antibody with high affinity. Also provided are compositions comprising panels of immunoreagents specific for multiple different target antigens and compositions comprising pairs of primary immunoreagents and their complementary detectable secondary antibodies. The paired primary immunoreagents and secondary antibodies are useful in a variety of immunologic assays, particularly in highly multiplexed assays, where the structure of the bridging antigen is varied in tandem with variation in the detectable secondary antibody, such that a multiplicity of immunoreagents are provided that are capable of simultaneously detecting a multiplicity of target antigens in a single assay.
    Type: Grant
    Filed: February 6, 2016
    Date of Patent: January 9, 2024
    Assignee: CELL IDX, INC.
    Inventor: David A. Schwartz
  • Publication number: 20230390280
    Abstract: The present disclosure provides a method of treating a fibrotic lung disease in a subject comprising administering to the subject an effective amount of a therapeutic agent, wherein the subject is asymptomatic and wherein the subject is at risk of developing the fibrotic lung disease.
    Type: Application
    Filed: September 8, 2022
    Publication date: December 7, 2023
    Inventors: David A. SCHWARTZ, Ivana V. YANG, Joyce S. LEE, Christopher M. EVANS, Marvin I. SCHWARZ
  • Publication number: 20230313307
    Abstract: The invention provides diagnostic and therapeutic targets for pulmonary disease, in particular, fibrotic lung disease. The inventors have found that a genetic variant MUC5B gene is associated with increased expression of the gene, increased risk of developing a pulmonary disease, and an improved prognosis and survival among those developing the pulmonary disease.
    Type: Application
    Filed: April 25, 2023
    Publication date: October 5, 2023
    Inventors: David A. Schwartz, Max Seibold
  • Patent number: 11753018
    Abstract: This document describes techniques and systems to make determinations of lane-type and roadway hypotheses in a road model. The road-perception system can fuse various forms of evidence to determine lane-type hypotheses and respective belief masses associated with the lane-type hypotheses. The road-perception system the computes, using the belief masses, a belief parameter and a plausibility parameter associated with the lane-type hypotheses. One or more roadway hypotheses are then determined using the lane-type hypotheses. The road-perception system then uses the respective belief parameter and plausibility parameter associated with the lane-type hypotheses to compute a belief parameter and a plausibility parameter associated with the roadway hypotheses. In this way, the described techniques and systems can provide an accurate and reliable road model with quantified uncertainty.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: September 12, 2023
    Assignee: Aptiv Technologies Limited
    Inventors: Bin Jia, David A. Schwartz
  • Publication number: 20230192094
    Abstract: This document describes techniques, apparatuses, and systems for a grid-based road model with multiple layers. An example road-perception system generates a roadway grid representation that includes multiple cells. The road-perception system uses data from multiple information sources to generate a road model that includes multiple layers. Each layer represents a roadway attribute of each cell in the grid and includes one or more layer hypotheses. In this way, the described techniques and systems can provide an accurate and reliable road model and quantify uncertainty therein.
    Type: Application
    Filed: February 23, 2023
    Publication date: June 22, 2023
    Inventors: Bin Jia, Sana Sarfraz, David A. Schwartz, Kumar Vishwajeet
  • Patent number: 11649503
    Abstract: The invention provides diagnostic and therapeutic targets for pulmonary disease, in particular, fibrotic lung disease. The inventors have found that a genetic variant MUC5B gene is associated with increased expression of the gene, increased risk of developing a pulmonary disease, and an improved prognosis and survival among those developing the pulmonary disease.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: May 16, 2023
    Assignee: National Jewish Health
    Inventors: David A. Schwartz, Max Seibold
  • Patent number: 11618453
    Abstract: This document describes techniques, apparatuses, and systems for a grid-based road model with multiple layers. An example road-perception system generates a roadway grid representation that includes multiple cells. The road-perception system uses data from multiple information sources to generate a road model that includes multiple layers. Each layer represents a roadway attribute of each cell in the grid and includes one or more layer hypotheses. In this way, the described techniques and systems can provide an accurate and reliable road model and quantify uncertainty therein.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 4, 2023
    Assignee: Aptiv Technologies Limited
    Inventors: Bin Jia, Sana Sarfraz, David A. Schwartz, Kumar Vishwajeet
  • Publication number: 20220334131
    Abstract: Disclosed herein are biomarkers related to preclinical pulmonary fibrosis and methods of identifying the same. In embodiments, the biomarkers are proteins. In embodiments, the biomarkers are transcripts.
    Type: Application
    Filed: May 18, 2020
    Publication date: October 20, 2022
    Inventors: David A. Schwartz, Ivana V. Yang, Susan k. Mathal
  • Publication number: 20220274601
    Abstract: This document describes techniques, apparatuses, and systems for a grid-based road model with multiple layers. An example road-perception system generates a roadway grid representation that includes multiple cells. The road-perception system uses data from multiple information sources to generate a road model that includes multiple layers. Each layer represents a roadway attribute of each cell in the grid and includes one or more layer hypotheses. In this way, the described techniques and systems can provide an accurate and reliable road model and quantify uncertainty therein.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 1, 2022
    Inventors: Bin Jia, Sana Sarfraz, David A. Schwartz, Kumar Vishwajeet
  • Publication number: 20220258738
    Abstract: This document describes techniques and systems to make determinations of lane-type and roadway hypotheses in a road model. The road-perception system can fuse various forms of evidence to determine lane-type hypotheses and respective belief masses associated with the lane-type hypotheses. The road-perception system the computes, using the belief masses, a belief parameter and a plausibility parameter associated with the lane-type hypotheses. One or more roadway hypotheses are then determined using the lane-type hypotheses. The road-perception system then uses the respective belief parameter and plausibility parameter associated with the lane-type hypotheses to compute a belief parameter and a plausibility parameter associated with the roadway hypotheses. In this way, the described techniques and systems can provide an accurate and reliable road model with quantified uncertainty.
    Type: Application
    Filed: February 17, 2021
    Publication date: August 18, 2022
    Inventors: Bin Jia, David A. Schwartz
  • Publication number: 20220170073
    Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.
    Type: Application
    Filed: July 7, 2021
    Publication date: June 2, 2022
    Applicants: The University of Chicago, EMD Millipore Corporation
    Inventors: David A. Schwartz, Jimmy Williams, Xinfang Zhao, Chunfang Zhao, William B. Busa, Stephen J. Kron, Amy Catherine Flor
  • Publication number: 20210198738
    Abstract: The invention provides diagnostic and therapeutic targets for pulmonary disease, in particular, fibrotic lung disease. The inventors have found that a genetic variant MUC5B gene is associated with increased expression of the gene, increased risk of developing a pulmonary disease, and an improved prognosis and survival among those developing the pulmonary disease.
    Type: Application
    Filed: November 6, 2020
    Publication date: July 1, 2021
    Inventors: David A. Schwartz, Max Seibold